US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Holding(s) in Company

TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BMCLYF79 Issuer Name 4BASEBIO PLC UK or Non-UK Issuer UK 2. Reason for Notification Other Comments Off-market transfer of Shares of the Issuer 3. Details of person subject to the notification obligation Name Sparta AG City of registered office (if applicable) Heidelberg Country of registered office (if applicable) Germany 4. Details of the shareholder Full name of shareholder(s) if different from the person(s) subject to the notification obligation,

Holding(s) in Company

TR-1: Standard form for notification of major holdings 1. Issuer Details ISIN GB00BMCLYF79 Issuer Name 4BASEBIO PLC UK or Non-UK Issuer UK 2. Reason for Notification Other Comments Off-market transfer of Shares of the Issuer 3. Details of person subject to the notification obligation Name SPARTA Invest AG City of registered office (if applicable) Heidelberg Country of registered office (if applicable) Germany 4. Details of the shareholder Full name of shareholder(s) if different from the person(s) subject to the notification

Employee Long Term Incentive Plan and Issue of Equity

18 July 2024   [A close-up of a logo Description automatically generated]          4basebio PLC ("4basebio" or the "Company")   Employee Long Term Incentive Plan and Issue of Equity   Cambridge, UK, 18 July 2024 - 4basebio PLC (AIM: 4BB), an innovation-led provider of novel synthetic DNA products and a non-viral, thermostable nucleic acid delivery platform announces that it has awarded 5,520 ordinary shares of EUR€1.00 each in the Company (“EBT Shares”) to the Employees Benefit Trust (“EBT”), operated by Fiduchi Trustees (UK) Limited at £15.60 per

Half-year Report

4basebio PLC("4basebio", the "Company" or the “Group”) Half-year Reportfor the six months ended 30 June 2023 4basebio PLC (AIM: 4BB), Cambridge, UK, 21 September 2023 – 4basebio PLC, an innovation driven biotechnology company enabling and accelerating development of advanced therapy medicinal products (ATMPs) through its high performant synthetic DNA products and non-viral, thermostable nucleic acid delivery platform, announces its unaudited half-year results for the six months ended 30 June 2023. Operational Highlights (including post period end) · DNA and Hermes™

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media